Judi Health Raised $400M at a $3.25B Valuation: How AJ Loiacono Built Capital Rx With Zero Marketing
September 7, 2026
TL;DR: Judi Health administers employee health benefits — pharmacy first, now medical and the longer tail of dental, vision and ancillary coverage — for self-insured employers, unions and health plans. It was founded in late 2017 by CEO AJ Loiacono and CTO Ryan Kelly under the name Capital Rx, and rebranded to Judi Health in September 2025. Its whole model is a refusal: unlike the incumbent pharmacy benefit managers, it does not make money on drug spend. It charges a flat administrative fee, and every customer gets the same price for the same drug. In September 2025 the company announced a $400 million investment, including a $252 million Series F led by Wellington Management and General Catalyst, doubling its valuation to $3.25 billion. It reports more than 4 million employer PBM members and over 54 million health plan lives contracted to the Judi platform. The part founders should study: Loiacono spent zero dollars on marketing for the first two years and still reached roughly $10–12 million in ARR. He told the story on The Product Market Fit Show.
What does Judi Health do?
Judi Health is a health benefit manager. If you get benefits through an employer, someone administers that plan — decides eligibility, processes the claim, applies the co-pay rules, pays the pharmacy. That administrator is usually a pharmacy benefit manager (PBM) owned by one of three enormous public companies.
Loiacono's objection is structural, not moral posturing about villains. Modern PBMs are vertically integrated: they own the administrator, the pharmacy, the rebate aggregator. So they get paid multiple times on the same transaction, and they get paid more when the drug costs more.
"The conflict of interest is, think about it, if you're asking someone to manage your benefit plan, and the more expensive the medication, the more money they make, that doesn't sound like a recipe for good outcomes for either the patient population or the plan's cost." — AJ Loiacono, Judi Health
Capital Rx went the other way, back to how the business worked before consolidation.
"We started as Capital Rx, and the concept was let's process these benefits, but unlike our competitors, let's not make money on drug spend." — AJ Loiacono, Judi Health
The technology underneath is a claims adjudication platform the company built itself, which is where the current name comes from.
"Judi's short for adjudication, which is a fancy word for claim processing." — AJ Loiacono, Judi Health
Adjudication is hundreds of workflows — eligibility, plan design, financial rule sets, clinical criteria, billing, reimbursement, call center, analytics, compliance. Loiacono's ambition was to run all of those in one system rather than stitching vendors together, which he describes as an ERP for healthcare.
Key stat: Judi Health has roughly 1,600 employees, of which about 500 are in product and engineering — Loiacono's figures on the show.
Who founded Judi Health?
Judi Health was founded in late 2017 by AJ Loiacono (CEO) and Ryan Kelly (CTO). It is Loiacono's third business; he had spent close to two decades in healthcare before starting it, beginning on the pharmaceutical manufacturing side.
That crossover is what produced the insight. On the manufacturing side, prices moved on a schedule — January and July, like clockwork. On the buy side, he found hundreds of prices for the same drug.
"But now I'm looking at prices on the insurance side. And you've got 600 prices in one quarter." — AJ Loiacono, Judi Health
His read on why is the sharpest line in the episode:
"Who loves opacity and variability? People that are seeking the highest level of profitability." — AJ Loiacono, Judi Health
Even the company's name was a deliberate, unglamorous choice: the domain was free, nobody held the trademark, and "Capital Rx" sounded like it had been around forever — which matters when you are asking a benefits committee to trust you with their employees' medication.
How much has Judi Health raised?
- Seed: $3.5 million, closed in March 2018 — Loiacono's number on the show. The company was an operating business by roughly that April.
- Series A: raised in year two, after the inbound Fortune 500 call convinced them the model would scale.
- September 2025: a $400 million investment, including a $252 million Series F led by Wellington Management and General Catalyst, with participation from Generation Investment Management, Growth Equity at Goldman Sachs Alternatives, 9Yards Capital, B Capital, Edison Partners, Prime Health Investments and Transformation Capital. The round doubled the valuation to $3.25 billion, and the company rebranded from Capital Rx to Judi Health at the same time.
The product market fit moment: an inbound call, two years in
Healthcare has a reference problem that makes the first two years brutal. A large employer will ask for a reference of similar scale before signing, so a new entrant is locked into small plans — 500 lives, 800 lives — and has to ladder up.
"You're selling to 500 life cases, 800 life cases. And you're trying to leverage, you know, those thousand life cases to get to two to four to, you know, eight, 16, et cetera." — AJ Loiacono, Judi Health
The moment everything changed was a phone call the company did not make.
"A Fortune 500 company called us directly, said, I saw this post that you made, and they said, I want to do business with you. And I was like, whoa." — AJ Loiacono, Judi Health
What is unusual is where the revenue already was when that happened:
"About 10, 12 million ARR at that point. Most founders of 10 million ARR feel like they're well beyond product market fit." — AJ Loiacono, Judi Health
He didn't feel it, because the yardstick was CVS, Cigna and UnitedHealthcare. Against Fortune 15 incumbents, $10 million in ARR is not proof of anything. The signal that mattered was not the number, it was a jumbo customer choosing to come to him.
How Judi Health competed with zero purchasing power
The obvious objection to the flat-fee model is that a startup cannot buy drugs as cheaply as a company with a hundred times its volume. Loiacono's answer was to concede the point and win on the other line of the income statement.
"So if you read my business plan at the start, it was we need to operate 70% more efficient than three Fortune 15 companies." — AJ Loiacono, Judi Health
That is the entire argument for building the adjudication platform rather than licensing one forever. Sales was harder still, because incumbents show a zero in the admin fee column while making their money inside the drug spend.
Never miss a founder's PMF story
Subscribe to The PMF ShowThen the regulatory environment moved. A 2021 amendment to ERISA inside the Consolidated Appropriations Act required full disclosure of healthcare compensation. Reporting obligations began to bite in 2023, and by 2024 buyers were asking every bidder the same question.
"2024, I often say, was this year in which transparency mattered." — AJ Loiacono, Judi Health
For a company whose revenue is one flat fee per claim, that disclosure was trivial to produce. For competitors with spread pricing, rebates, 340B and performance fees, it was not.
Zero marketing for two years: the referral engine
Judi Health's go-to-market for the first two years was not a growth strategy in any modern sense.
"So we did zero marketing the first two years. Zero." — AJ Loiacono, Judi Health
No sponsorships, no conferences, no paid search, and a $2,000 press release was an argument. The money went into service instead.
"And my thought was, let's spend the money to make sure we operate at the highest level of service. And then our customers will become our brand managers." — AJ Loiacono, Judi Health
Concretely, that meant: an in-house domestic call center, no cap on average handle time, and a target of first-call resolution above 97%. It meant on-site annual reviews with every customer, however small, which is why Loiacono spent those years in rental cars around Pennsylvania, Maryland, Delaware and Connecticut. And it meant unions and municipalities as the first market — they have fixed budgets, so they care about cost in a way a Fortune 500 plan absorbing a 5% increase does not.
Today the referral loop is systematized: an annual customer survey that asks two specific questions — can we use you as a reference, and would you speak at a conference or on a panel.
Loiacono also still personally manages two of the company's oldest accounts.
"I'm still the client manager on two of our oldest accounts." — AJ Loiacono, Judi Health
Key lessons from AJ Loiacono's playbook
1. In a trust-driven market, service is distribution. Loiacono is explicit that this may not generalize to every industry, but in healthcare a reference from a peer beats any campaign. Spend the marketing budget on first-call resolution instead. 2. Concede the advantage you cannot win and pick a different axis. He could not out-purchase CVS. He wrote a business plan around being 70% more operationally efficient than his competitors instead. 3. Revenue is not the same as product market fit. $10–12 million in ARR did not convince him. An unsolicited inbound from a customer 30x his usual size did. 4. Hire for mission, and never ask about it directly. Judi Health's interviews avoid the question; they listen for whether a candidate raises a bad personal healthcare experience unprompted. Loiacono says the people from year one who are still there all did. 5. Know what an A player actually means. His definition: "D players see a problem and say nothing... The A players see something and fix it, and I never knew it even was a problem." 6. Strip out anything that only feels like a startup. Pantone choices, pizza Fridays, brand polish before there is a business.
"You have to treat your startup like this is the only money you're ever going to see in your life." — AJ Loiacono, Judi Health
"There's no safety net. There's no series B. There's no series C. We need to spend this money as if it's the only oxygen left in the room." — AJ Loiacono, Judi Health
For related stories on founders taking on entrenched incumbents in regulated markets, see Flo Health's road to a $1B valuation and Neo Financial taking on Canada's banks.
FAQ: Judi Health
Q: What is Judi Health? A: Judi Health is a health benefit manager for self-insured employers, unions and health plans. It administers pharmacy and medical benefits on its own claims adjudication platform, called Judi, and charges a flat administrative fee rather than earning money from drug spend.
Q: Is Judi Health the same company as Capital Rx? A: Yes. The company was founded as Capital Rx in late 2017 and rebranded to Judi Health in September 2025, alongside its $400 million funding announcement, to reflect its expansion beyond pharmacy benefits.
Q: Who is the CEO of Judi Health? A: AJ Loiacono, who co-founded the company with CTO Ryan Kelly. It is his third company, and he spent roughly two decades in healthcare — starting on the pharmaceutical manufacturing side — before founding it.
Q: How much funding has Judi Health raised? A: The company raised a $3.5 million seed round that closed in March 2018, and in September 2025 announced a $400 million investment including a $252 million Series F led by Wellington Management and General Catalyst, at a $3.25 billion valuation.
Q: Who does Judi Health compete with? A: The three vertically integrated incumbents that dominate US pharmacy benefits — CVS, Cigna and UnitedHealthcare — all of which are Fortune 15 companies.
Q: How big is Judi Health? A: On the show Loiacono put headcount at roughly 1,600, including about 500 in product and engineering. The company reports more than 4 million employer PBM members and over 54 million health plan lives contracted to its platform.
Sources: Listen to the Full Founder Story
- AJ Loiacono, Co-Founder & CEO of Judi Health (formerly Capital Rx) — took on the three companies that control US pharmacy benefits with a flat-fee model, zero marketing spend and an in-house call center.
Listen to the full episode at pmf.show for the complete story.
Last updated: September 2026
Want more founder stories like this?
Subscribe to The Product Market Fit Show for weekly episodes.
Subscribe Now